Biosimilar switch for asthma and hives under Real-World study

NCT ID NCT07425639

Recruiting now Disease control Sponsor: Celltrion HealthCare France Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is observing 225 adults with severe allergic asthma or chronic hives who are already doing well on the original omalizumab drug. Their doctors have decided to switch them to a biosimilar version called Omlyclo. The main goal is to see if they stay well-controlled for 12 months after the switch, and how satisfied they are with the new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: omalizumab biosimilar (Omlyclo)
What this could lead to: If successful, this study could show that switching to a biosimilar is a safe and effective option for managing chronic inflammatory conditions, potentially lowering treatment costs.
What could go wrong: This is an observational study, not a controlled trial, so results may be less definitive. It only includes patients already stable on the original drug, so findings may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALLERGIC ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

allergic asthma chronic asthma chronic idiopathic urticaria Chronic Urticaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALLERGIC ASTHMA CHRONIC SPONTANEOUS URTICARIA (CSU)

Contacts and locations

Locations

CHU Montpellier
RECRUITING

Montpellier, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.